Le Lézard
Classified in: Health
Subject: ACC

Hansa Biopharma: Issue and Re-purchase of Class C Shares for Incentive Programme


LUND, Sweden, Sept. 2, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that by virtue of the authorisation by the annual general meeting held on 22 May 2019, the board of directors of Hansa Biopharma AB (publ) has resolved to issue and immediately thereafter re-purchase 715,910 class C shares. The shares are issued and re-purchased in accordance with the incentive programme LTIP 2019, which was adopted by the annual general meeting held on 22 May 2019.

Carnegie Investment Bank AB (publ) will subscribe for the entire issue of new class C shares at a subscription price of SEK 1 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the board of directors' resolution, be re-purchased by Hansa Biopharma for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2019.

The purpose of the re-purchase is to ensure delivery of shares to participants and to secure possible social charges arising as a result of LTIP 2019. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right. Hansa Biopharma has previously issued 705,547 class C shares.

For further information, please contact:

Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma--issue-and-re-purchase-of-class-c-shares-for-incentive-programme,c2893468

The following files are available for download:

https://mb.cision.com/Main/1219/2893468/1098822.pdf

Hansa Biopharma: Issue and re-purchase of class C shares for incentive programme

SOURCE Hansa Biopharma AB


These press releases may also interest you

at 18:55
Resverlogix Corp. ("Resverlogix" or the "Company") is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET. The Company also announces its participation at the 57th ERA-EDTA...

at 18:10
TALTZ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually today at the European Congress of Rheumatology 2020 (EULAR). Eli Lilly and Company shared...

at 17:47
The U.S. Food and Drug Administration today continued to take action in the ongoing response to the COVID-19 pandemic: The FDA issued an updated FDA COVID-19 Response At-A-Glance Summary that provides a quick look at facts, figures and highlights of...

at 17:30
The "Bioresorbable Medical Material Market to 2027 - Global Analysis and Forecasts by Product Type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering. The bioresorbable medical material market was valued at US$...

at 17:26
The healthcare system in the Commonwealth of Dominica was not strained by the pandemic, with the government managing to contain the spread of the virus from the onset, recording zero deaths and only 16 fully recovered cases. Nonetheless, the...

at 17:25
Since the week of March 12, the Ontario Health Coalition has been tracking all people who have been infected with COVID-19 in outbreaks in health care settings including hospitals, long-term care, retirement homes, public health units, clinics and...



News published on 2 september 2019 at 11:15 and distributed by: